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Abstract: Nasopharyngeal (NP) lymphoma is a rare primary malignancy of the head and neck and
represents a minority of malignancies originating from the nasopharynx. For this reason, there are
limited data regarding epidemiologic and treatment outcomes. This is a retrospective review of
patients diagnosed with NP lymphoma from 1995 to 2017 at a tertiary medical center. The patients’
demographic data, clinical presentations, treatment modalities, Epstein–Barr virus (EBV)-encoded
small RNA (EBER) staining, and outcomes were investigated. We considered a total of 35 patients,
including 20 males and 15 females, diagnosed with NP lymphoma. The age ranged from 17 to 88
years (mean = 59.6). The common presentations were nasal obstruction, epistaxis, and neck mass.
In our study, the most common pathological diagnosis of NP lymphoma was diffuse large B cell
lymphoma (DLBCL) (n = 17), followed by NK/T cell lymphoma (NKTCL) (n = 9). Other pathologic
diagnoses included extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
(MALToma), small lymphocytic lymphoma, mantle cell lymphoma. There were 13 cases showing
EBER positivity, including 7 cases of NKTCL, 5 cases of DLBCL, and 1 case of post-transplant
lymphoproliferative disorder (PTLD). Most patients received chemotherapy alone, while some
patients received both chemotherapy and radiotherapy. Seven patients had local recurrence, and
fewer than half of the patients (n = 16) were alive at the time of the study (mean follow-up duration:
54.4 months). The five-year overall survival was 50.4%. NP lymphoma is very rare, and the most
common pathologic type is DLBCL. EBER positivity is found in both NKTCL and DLBCL. Identifying
more effective therapeutic agents is extremely important to improve patients’ survival.
Keywords: nasopharynx; lymphoma; EBER; DLBCL; NKTCL
1. Introduction
Lymphoma, the most common non-epithelial malignancy of the head and neck region, can
be classified into two types, Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL) [1].
J. Clin. Med. 2019, 8, 1604; doi:10.3390/jcm8101604 www.mdpi.com/journal/jcm
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Among them, primary nasopharyngeal (NP) lymphoma is a very rare tumor, with only limited studies
found in the literatures [2–10]. Waldeyer-Hartz firstly described the lymphoid tissues within the
nasopharynx, oropharyngeal wall, base of the tongue, palatine tonsils, and soft palate, known today as
Waldeyer’s ring (WR) [7]. It has been reported that less than 10% of NHL cases in Western countries
involved the WR (WR-NHL) [11–13], while 10–18% of NHL cases were WR-NHL in Asian countries [7].
Among WR-NHL, about 35–37% of cases were at the nasopharyngeal site, and there was no difference
of incidence between Western and Asian countries [7,9].
NP lymphoma is a rare extranodal lymphoma with a variety of histopathologic subtypes, and
the incidences of different subtypes are quite different among different areas [7,9]. Diffuse large B
cell lymphoma (DLBCL) and NK/T cell lymphoma (NKTCL) are the two most common pathologic
diagnoses [7,9]. Epstein–Barr virus (EBV) has been known to be related to lymphoma pathogenesis.
However, related studies in NP lymphoma are very few. EBV-associated viral proteins were
found to play important roles in the genesis of lymphomas through several mechanisms [10,14–17].
The expression of EBV-encoded small RNAs (EBER) is common in NKTCL, while EBER positivity is
still controversial in DLBCL [10,18–22]. There are studies reporting that EBER-positive patients have a
poorer prognosis than EBER-negative patients [10,23].
So far, there are relatively few data regarding NP lymphomas, especially in areas with
high incidence of nasopharyngeal carcinoma (NPC). The aim of this study was to analyze the
clinicopathologic characteristics and survival of NP lymphoma patients at a tertiary medical center
in Taiwan. Subgroup analyses was also conducted to further identify the association between EBER
positivity and the clinical features of NP lymphomas. This is one of the only two studies investigating
EBER expression in NP lymphoma [4].
2. Materials and Methods
2.1. Patient Population
We retrospectively reviewed the records and data of patients who had undergone NP biopsy
demonstrating pathology-proven lymphoma at Taipei Veterans General Hospital in Taipei, Taiwan,
between 1 January, 1995 and 31 October, 2017. The Institutional Review Board (IRB) of Taipei
Veterans General Hospital approved this study. All procedures performed in studies involving
human participants were in accordance with the ethical standards of the institutional and/or national
research committee and with the 1964 Helsinki declaration and its later amendments or comparable
ethical standards.
The diagnostic criteria for lymphoma were based on the World Health Organization
classification [1] using both morphologic and immunohistochemical evaluations. All patients were
staged according to the Ann Arbor staging system [24]. Data including sex, age, tumor stage (according
to Ann Arbor classification), underlying medical comorbidities (hypertension, diabetes, or coronary
artery disease), initial clinical presentation, duration of symptoms, pathology, treatment modalities
and outcomes, and survival time, were reviewed. Immunohistochemistry (IHC) and EBERs in situ
hybridization (ISH) examinations were used for pathologic diagnoses. The diagnoses of all cases were
reviewed and confirmed.
2.2. ISH of EBERs
ISH studies were performed on formalin-fixed, paraffin-embedded tissues. Tissue sections were
deparaffinized according to established procedures. Antigen retrieval was performed using the
Enzyme Pretreatment Kit (AR9551, Leica Biosystems Newcastle Ltd, UK) for 5 min at 37 ◦C. We used
the Bond™ Ready-to-Use ISH EBER Probe (PB0589, Leica Biosystems Newcastle Ltd, UK) as the
primary antibody for 90 minutes. Slides were then stained using Bond™ Polymer Refine Detection
(DS9800, Leica Biosystems Newcastle Ltd, UK) with the Leica Biosystems BONDMAX autostainer
(Leica Biosystems Newcastle Ltd, UK), according to the manufacturer’s instructions. Briefly, an
J. Clin. Med. 2019, 8, 1604 3 of 16
anti-fluorescein antibody was used for 15 minutes, followed by the post-primary IgG linker reagent
which localized the mouse antibody for 4 minutes, and the poly-HRP IgG reagent which localized
the rabbit antibody for 4 minutes. Staining was then developed with the substrate chromogen DAB
(3,3’-diaminobenzidine tetrahydrochloride) for 10 minutes. Finally, the sections were counterstained
with modified Mayer’s hematoxylin for 10 minutes.
2.3. Statistical Analysis
Quantitative data were summarized as mean ± standard deviation (SD), and categorical variables
as percentages. IBM SPSS 20.0 software (IBM Corp, Armonk, NY, USA) was used for statistical analyses.
Categorical data were compared using the chi-square test. The Kaplan–Meier method was used
for estimating overall survival (OS), defined as the time in months from diagnosis to death or last
follow-up due to any cause. Differences in survival were compared using the log-rank test. All tests
were two-tailed and conducted considering a 5% significance level.
3. Results
3.1. Patients
We considered a total of 35 patients, including 20 males and 15 females, diagnosed with NP
lymphoma at Taipei Veterans General Hospital between 1995 and 2017. The age at diagnosis ranged
from 17 to 88 years (mean 59.6). Ten patients had hypertension, six had diabetes, and four had coronary
artery disease. The most common presenting signs and symptoms included nasal obstruction (28.9%,
n = 10), epistaxis (25.7%, n = 9), neck mass (22.9%, n = 8), purulent rhinorrhea (17.1%, n = 6), headache
(14.3%, n = 5), and B symptoms (14.3%, n = 5) (Table 1). The average time window between initial
symptoms to diagnosis ranged from 0.5 to 12 months (mean 2.6 months). The average white blood cell
count (WBC) was 12,992 cells/cm3 (2400–167,800), and the average lactic dehydrogenase (LDH) level
was 337.7 U/L (106–1702).
In our study, the most common pathological diagnosis of nasopharyngeal lymphoma was
DLBCL (48.6%, n = 17), followed by NKTCL (25.7%, n = 9). Other pathologic diagnoses included
extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALToma) (8.6%, n = 3),
small lymphocytic lymphoma (5.7%, n = 2), mantle cell lymphoma (5.7%, n = 2), B lymphoblastic
leukemia/lymphoma (2.9%, n = 1), and post-transplant lymphoproliferative disorder (PTLD) (2.9%,
n = 1) (Figure 1).
Table 1. Demographic, clinical, and histological information of patients with NP lymphoma.
Case Number (n = 35)
Age 17–88 (mean 59.57 ± 18.84)
Sex M/F = 20/15
Symptoms
Nasal obstruction 10 (28.6%)
Epistaxis 9 (25.7%)
Neck mass 8 (22.9%)
Purulent Rhinorrhea 6 (17.1%)
Headache 5 (14.3%)
B symptoms 5 (14.3%)
Symptom Duration 0.5–12 (mean 2.61 ± 2.97)
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Table 1. Cont.
Case Number (n = 35)
Location of Disease
NP only 22 (62.9%)
NP + neck/distant LN * 10 (28.6%)
NP + adjacent organ # 3 (8.6%)
Comorbidity
HTN 10 (28.6%)
DM 6 (17.1%)
CAD 4 (11.4%)
Lab
WBC 2400–167800 (mean 12992)
LDH 106–1702 (mean 337.7)
EBER
Positive 13 (37.1%)
Negative 19 (54.3%)
NA 3 (8.6%)
Stage (Ann Arbor)
I 12 (34.3%)
II 15 (42.9%)
IV 8 (22.9%)
Treatment
CT 20 (57.1%)
RT 1 (2.9%)
CT+RT 6 (17.1%)
CT+PBSCT 5 (14.3%)
CT+RT+PBSCT 2 (5.7%)
No treatment 1 (2.9%)
Recurrence 8 (22.9%)
Dead 19 (54.3%)
# sinonasal cavity, oropharynx, hypopharynx; *gastrointestinal (GI) tract, inguinal lymph node (LN), neck LN.
Abbreviation: CT: chemotherapy; RT: radiotherapy; PBSCT: peripheral blood stem cell transplantation; EBER:
Epstein–Barr virus-encoded small RNAs; NA: not available; HTN: hypertension; DM: Diabetes mellitus; CAD:
Coronary artery disease; WBC: white blood cell count; LDH: lactic dehydrogenase.
As for tumor location, most of the tumors (62.9%, n = 22) were located in the nasopharynx only
(Figures 2 and 3). Some of the tumors (n = 3) extended to adjacent sites, including the paranasal sinuses,
nasal cavity, oral cavity, and oropharynx. Ten cases (28.6%) had neck lymph nodes involvement or
other distant involvements when diagnosed. On the basis of the Ann Arbor staging system, 12 patients
(34.3%) had stage I, 15 patients (42.9%) had stage II, and 8 patients (22.9%) had stage IV lymphoma.
The characteristics of stage IV cases are listed in Supplementary Table S1. There were no cases with
central nervous system (CNS) involvement in our series.
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Figure 1. Histological subtypes of nasopharyngeal (NP) lymphoma. Abbreviations: DLBCL: diffuse
large B cell lymphoma; NKTCL: NK/T cell lymphoma; MALToma: extranodal marginal zone lymphoma
of mucosa-associated lymphoid tissue; PTLD: post-transplant lymphoproliferative disorder.
Figure 2. MRI and CT images of NP lymphomas. (A) An 85-year-old female diagnosed with NP
DLBCL. The MRI revealed that the tumor involved the right NP and right parapharyngeal space. (B)
A 73-year-old male diagnosed with NP NKTCL. The CT scan revealed that the tumor involved the
right NP.
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Figure 3. Endoscopic views of various NP lymphomas. Endoscopic examinations showed various NP
lymphomas, which were heterogeneous, from smooth bulging masses to hemorrhagic masses, and
some tumors showed necrosis over their surface: (A,B) small lymphocytic lymphoma, (C,D,E) DLBCL,
(F) NKTCL, (G,H) mantle cell lymphoma, (I) MALToma.
3.2. EBERs
Regarding EBER staining, 13 cases were EBER-positive, including 7 cases of NKTCL, 5 cases
of DLBCL, and 1 case of PTLD (Table 1) (Figures 4 and 5). There were three cases for which EBER
staining was not possible because of insufficient specimen, including one case of DLBCL and two cases
of NKTCL.
Figure 4. Pathologic images of NP-DLBCL. The hematoxylin and eosin (H&E)-stained slide shows
diffuse proliferation of large atypical lymphoid cells. The neoplastic cells are positive for CD20
and EBER.
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Figure 5. Pathologic images of NP-NKTCL. The H&E-stained slide shows diffuse proliferation of small
to medium sized lymphoid cells. The neoplastic lymphoid cells are positive for CD3, CD56, and EBER.
3.3. Treatment Modality
Most of the patients (94.3%, n = 33) received chemotherapy (CT). Only one patient received
radiotherapy (RT) alone; 22.9% of patients (n = 8) received both CT and RT. Some patients (22.9%,
n = 8) also received peripheral blood stem cell transplantation (PBSCT) after primary treatment.
3.4. Survival
Although there was no significant difference of OS between patients receiving CT alone or
combined chemoradiotherapy, a higher 10-year OS was observed in patients receiving combined
therapy (41.7% vs. 31.2%). Fewer than half of the patients (n = 16) were alive at the last follow-up.
Two-year, 5-year, and 10-year OS were 67.9%, 50.4%, and 33.6%, respectively. OS was not correlated
with sex (p = 0.816), B symptoms (p = 0.305), age (p = 0.414), and Ann Arbor stage (p = 0.959).
3.5. Recurrence
There were eight patients (22.9%) who experienced recurrence, including five patients (62.5%)
with neck recurrence, two patients with distant recurrence (lung and thigh), and one patient with local
(NP) recurrence.
3.6. Subgroup Analysis
A comparison of the main clinical characteristics of NP DLBCL (NP-DLBCL) and NKTCL
(NP-NKTCL) patients is shown in Table 2. The ratio of males to females was 1.125:1 in NP-DLBCL and
2:1 in NP-NKTCL. Patients with NP-DLBCL tended to present with regional lymph node involvement
and stage IV disease. Among several clinical characteristics, only duration of symptoms and EBER
expression had significant differences between the two groups. The mean duration of symptoms in
NP-DLBCL patients was 1.53 months, while the mean duration of symptoms in NP-NKTCL patients
was 4.33 months (p = 0.009). For cases with EBER ISH data (n = 32), all NP-NKTCL revealed EBER
positivity (n = 7), while 5 out of 16 cases of NP-DLBCL showed EBER positivity. More cases of
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NP-DLBCL received CT only (75% vs. 55.6%), while more cases of NP-NKTCL received combined CT
and RT (44.4% vs. 25%). The mean OS rate of NP-DLBCL patients was 84.4%, which was higher than
the mean OS rate of NP-NKTCL patients (57.2%), but this difference was not statistically significant
(p = 0.413) (Table 2) (Figure 6).
Table 2. Demographic and histopathological characteristics of NP-DLBCL and NP-NKTCL patients.
DLBCL(n = 17) NKTCL(n = 9)
Characteristic No (%) No (%) P value
Sex 0.683
male 9 (52.90%) 6 (66.70%)
female 8 (47.10%) 3 (33.30%)
Age 61.59+/-22.49 (17-88) 59.44+/-17.27 (38-81) 0.806
Duration(months) 1.53+/-0.86 (0.5-4) 4.33+/-3.94 (1-12) 0.009
Stage 0.324
I 4 (23.50%) 5 (55.60%)
II 8 (47.10%) 3 (33.30%)
IV 5 (29.40%) 1 (11.10%)
Location of Disease 0.822
NP only 11 (64.70%) 7 (77.80%)
NP+ neck/distant LN * 4 (23.50%) 1 (11.10%)
NP+ adjacent organ # 2 (11.80%) 1 (11.10%)
EBER † 0.005
Positive 5 (31.25%) 7 (100%)†
Negative 11 (68.75%) 0 (0%)
B symptoms 1 (5.90%) 2 (22.2%) 0.268
Cervical Node Involvement 4 (23.50%) 0 (0%) 0.263
Treatment 0.394
CT only 12 (75%) 5 (55.60%)
CT+RT 4 (25%) 4 (44.40%)
Recurrence * 4 (23.53%) 1 (11.10%) 0.628
Dead 10 (58.82%) 6 (66.70%) 1
Overall survival 25.90% 16.10% 0.515
3-year 64.70% 55.60% 0.505
5-year 48.50% 55.60% 0.803
10-year 38.80% 18.50% 0.417
# sinonasal cavity, oropharynx, hypopharynx, * GI tract, inguinal LN, neck LN. † There were 3 missing data, 1 of
DLBCL and 2 of NKTCL.
Figure 6. Overall survival of 35 patients with NP lymphoma in our study.
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4. Discussion
NP lymphoma is a rare extranodal hematologic malignancy with a variety of underlying
histopathologic subtypes. Although the incidence of the subtypes of NP lymphoma has been reported
to be different in different areas of the world [2–7,9,10], NP lymphoma is broadly classified into two
types, HL and NHL. NHL accounts for the majority of lymphomas, about 86% of lymphoma cases in
the Western population and 90% of lymphoma cases in the Asian population [25–27]. Among NHL,
B cell lymphoma is the most common lymphoma in western countries, making up more than 90%
of NHL cases [26,28], but is less common in Asian countries (64.3%) [27]. B cell lymphoma is also
naturally more common among NP lymphomas, with 52.5% of cases in the Asian population and
77.5% of cases in the Western population, respectively [7,9]. In contrast, NKTCL accounts for 47.5% of
NP lymphomas in the Asian population, while it accounts for only 6% of NP lymphoma in the Western
population [7,9].
The WR is an uncommon site for NHL, with only 10–18% of NHL in Asia occurring in WR in
Asia [5,29,30]. In Wu et al.’s study, NP presented as the primary site of tumor location in 26% of
WR-DLBCL and in 66% of WR-NKTCL. Regarding NP lymphoma, the most common histological
type was reported to be B-cell lymphoma (48.6–87.6% of NP lymphoma) [2,6,9,31]. In our study, the
most common NP lymphoma was also DLBCL (48.6%), followed by NKTCL (25.7%), and poorer
prognosis was noted for NKTCL compared to DLBCL. Other rare subtypes of NP lymphoma included
MALToma (8.6%), small lymphocytic lymphoma (5.7%), mantle cell lymphoma (5.7%), B lymphoblastic
leukemia/lymphoma (2.9%), and PTLD (2.9%) (Figure 1). Han et al reported that 2.9% of NP lymphoma
cases were HL [9]. However, there were no cases of HL in our study. Compared to the western
literature, the incidence of NKTCL in our study was relatively high [9] (Table 3).
In our study, the average age of the patients was 59.6 years, and there was a slight male
preponderance, similar to previous studies of NP lymphoma [2–4,9]. However, we did not find any
correlation between sex or age and survival, which is different from what previously reported [2,9,32].
These conflicting results may be due to different sample sizes and races examined in different studies.
Symptoms and signs of NP lymphoma include neck mass (69–85%), epistaxis (19-33%), hearing
loss (8–23%), nasal discharge (15–51%), and nasal obstruction (50–88%) [3,6]. Since all of these
symptoms may occur in patients with any NP mass, it is important to differentiate NP lymphomas
from other NP tumors. The major difference is that some patients with NP lymphomas may suffer from
constitutional symptoms (18–27%), the so-called B symptoms, including weight loss, night sweats,
and fevers, which are less common in patients with other NP tumors [3,6,9]. However, some patients
may have no symptoms at diagnosis [33]. Naturally, the only method for a definite diagnosis is a
biopsy-based pathological analysis. In our study, the common symptoms included nasal obstruction
(28.9%), epistaxis (25.7%), neck mass (22.9%), purulent rhinorrhea (17.1%), headache (14.3%), and B
symptoms (14.3%). Cervical nodal involvement was relatively limited in our study compared to other
studies [6]. Moreover, neck lymph node involvement was only found in cases with NP-DLBCL. B
symptoms have been reported to be associated with poor prognosis [34], but this correlation was not
confirmed in our study.
The average duration of the symptoms before the diagnosis of NP lymphoma was not mentioned
in related studies. However, there was a study regarding a lymphoma of the nasal cavity and paranasal
sinuses, in which the average duration of the symptoms was 5.9 months prior to diagnosis [35]. In the
same study, improved survival was found in patients who had symptoms for less than 3 months (70%)
compared with those who had symptoms for more than 3 months (25%) [35]. In our study, the average
time from initial symptoms to diagnosis ranged from 0.5 to 12 months (mean 2.6 months), and there
was a significant difference of symptom duration between NP-DLBCL and NP-NKTCL (1.53 months
vs. 4.33 months, p = 0.009). Because most symptoms of NP lymphoma are non-specific, patients may
be diagnosed late when they are at an advanced stage. Therefore, it is important to be cautious when
approaching patients with these symptoms.
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Table 3. Summary of studies of NP lymphoma.
Year Author Country No. Age
Sex
(M/F)
Tumor Pathology EBER
(+)
Treatment Survival
(OS)DLBCL NKTCL Other CT RT CT + RT
1999 Lei [2] China 19 51 15/4 11(57.9%) 5(26.3%) 3(15.8%) NA 6(32%) 2(11%) 11(58%) 5-Y OS:82%5-Y DFS:76%
2006 Laskar [3] India 113 40 79/34 94(83.2%) 0T-cell 19(16.8%) NA 25(22%) 0(0) 86(76%)
5-Y OS:57.9%
5-Y DFS:55.8%
2 expired before treatment
2006 Zou [5] China 80 NA NA 48(60%)B-cell 32(40%) 0 NA 31(38.8%) 7(8.8%) 42(84%)
5-Y OS
B-cell origin: 69.5%
NKTCL: 35.5%
5-Yprogression-free survival:
B-cell origin: 53.3%
NKTCL: 28.9%
2006 Mitarnun [4] Thailand 42 57.2 24/18 35(83.3%) 3(7.1%) 4(9.5%) 9/42(21.4%) NA NA NA NA
2009 Allam [6] Morroco 26 52.7 NA 13(50%) 4(15.4%)T cell 9(34.6%) NA 27% 0(0) 73%
1-Y OS:87%
1-Y DFS: 71%
DLBCL:2-Y OS:75%
2014 Wu [7] China 61 49all WR NA 32(52.5%) 29(47.5%) 0 NA NA NA NA
WR-NKTCL
5-Y OS:68%
WR-DLBCL
5-Y OS: 74%
2017 Han [9] USA 1119 59.3 658/461 867(77.5%)B-cell 67(6.0%) 185(16.5%) NA NA 452(41.5%) NA
2-Y OS:70%
5-Y OS:57%
10-Y OS:45%
2-Y DSS:77%
5-Y DSS:68%
10-Y DSS:62%
2019 Hsueh Taiwan 35 59.6 20/15 17(48.6%) 9(25.7%) 9(25.7%) 13/32(37.1%) 25(71.4%) 1(2.9%) 8(22.9%)
DLBCL:
3-Y OS:64.7%
5-Y OS:48.5%
10-Y OS:38.8%
NKTCL:
3-Y OS:55.6%
5-Y OS:55.6%
10-Y OS:18.5%
Abbreviations: WR: Waldeyer’ ring; DLBCL: diffuse large B cell lymphoma; NKTCL: NK/T cell lymphoma; NP: nasopharynx; CT: chemotherapy; RT: radiotherapy; OS: overall survival;
DSS: disease specific survival; DFS: disease free survival; EBER: Epstein–Barr virus-encoded small RNAs.
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In southern Asia, NPC is a relatively common malignancy. Its incidence in southern China is
estimated to be approximately 10–50 cases per 100,000 [36], while the incidence is rare in Western
countries, around 2.2/100,000 [37]. In Taiwan, the latest cancer registry data released by the government
showed that the incidence of NPC is 3.2–9.8 per 100,000, while the incidence of NHL is around 9.1–11.9
per 100,000 [38]. Therefore, it is important to differentiate NP lymphomas from NPC in patients
presenting with NP tumors in endemic areas with a high incidence of NPC, such as Taiwan.
Treatments for lymphoma include systemic CT, RT, PBSCT, targeted therapy (e.g., anti-CD20), and
combined therapy [39]. B-Cell NHL has been found to be more sensitive to anthracycline-based CT
than NKTCL [40]. Wu et al. also found that WR-DLBCL was more responsive to chemotherapy than
WR-NKTCL [7]. The suitable treatment modality usually depends on the subtype of the lymphoma.
Miller et al. reported that CT followed by involved-field RT was superior to CT alone for the treatment
of localized intermediate- and high-grade NHL [41]. Aviles et al. focused on WR-NHL and revealed
that OS was better for patients in the combined-therapy arm (90%) than for those in the CT arm (58%)
and RT arm (56%) [42]. Han et al. has proposed that RT is a positive prognostic indicator for NP
lymphomas, with the exception of NKTCL [9].
Because this is a retrospective study, there were heterogeneous treatment modalities for the NP
lymphoma patients. In our study, more than 90% (n= 33) of patients received CT, while only one patient
diagnosed with MALToma received RT alone, and this patient had a 25.7-month disease-free survival
time. Among patients who received CT (n = 33), 24.2% of them (n = 8) also received RT concomitantly
or sequentially. More cases of NP-DLBCL received CT alone, while more cases of NP-NKTCL received
combined CT and RT. The five-year OS was 54.5% in the CT group and 41.7% in the combined
chemoradiotherapy group, but there was no significant difference. However, a higher 10-year OS was
observed in patients who received combined therapy. In subgroup analysis, the OS of DLBCL patients
receiving CT and combined chemoradiotherapy were 90.0 months and 87.0 months, respectively
(p = 0.920). In the subgroup of NKTCL, the OS of CT-treated and combined chemoradiotherapy-treated
patients was 36.7 months and 81.2 months, respectively (p = 0.260). Interestingly, studies regarding the
Western population showed no evidence of survival benefit from RT for DLBCL patients, but a trend
of improved survival after combined chemoradiotherapy was found for our NKTCL patients [43].
Regarding OS of NP lymphomas, Han et al. [9] reported a five-year OS of 57%, while Allam et al. [6]
reported a two-year OS rate of 75%, and Laskar et al. reported a five-year OS of 57.9% [3]. In our study,
the 2-year, 5-year, and 10-year OS rates were 67.9%, 50.4%, and 33.6%, respectively, which is similar to
what reported in other studies. The mean OS of NP-DLBCL and NP-NKTCL patients were 84.4% and
57.2%, respectively, but without statistically significant difference. Similar to Zou et al.’s study, worse
survival was found in NP-NKTCL patients compared to patients with early-stage NP B-cell lymphoma
(five-year OS: 35.5% vs. 69.5%, p = 0.003) [5]. Yang et al. classified early-stage NKTCL patients into
low- and high-risk groups based on age, Eastern Cooperative Oncology Group (ECOG) status, stage
II disease, LDH levels, and primary tumor invasion (PTI) [44]. The study found that primary RT
improved survival for early-stage NKTCL patients [44]. RT followed by CT improved survival in the
high-risk group. In the low-risk group, the five-year OS rate was 88.8% for patients receiving RT alone
and 86.3–86.9% for patients receiving combined CT and RT, while it was 72.2% for patients receiving
CT after RT and 58.3–59.6% for patients receiving RT after CT or RT alone in the high-risk group [45].
Lee et al. reported that in Ann Arbor stage I–II sinonasal DLBCL patients, there was no difference in
survival between patients receiving CT alone and those receiving combined CT and RT [43]. In our
study, for the NP-NKTCL patients, superior survival was observed for patients receiving combined
CT and RT compared to the patients receiving CT alone (81.7% vs. 36.9%). However, similar OS was
observed for patients with NP-DLBCL, no matter whether the patient received combine CT and RT or
CT alone. This implies that NP-NKTCL might be more sensitive to RT than NP-DLBCL.
Recurrence rate and sites of recurrence are highly variable in the literature [2,6]. In our study,
eight cases (22.9%) had recurrence, including two cases (20%) of DLBCL and one case (11.1%) of
NKTCL. According to Wu et al., 50% of patients with WR-DLBCL and 64% of patients with WR-NKTCL
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had relapse at extranodal sites, with WR-DLBCL having significantly more extensive lymph node
involvement than WR-NKTCL [7]. Lee et al. proposed that the relapse rate for DLBCL was 13.8%, with
local recurrence being the most common recurrence type [43]. Interestingly, for the eight recurrent
cases in our study, the most common recurrence site was the neck (62.5%), and only one patient had
local recurrence (12.5%).
EBER positivity for both NPC and NKTCL is very high. However, the frequency of EBER positivity
for DLBCL in different geographic regions varies, being higher in Asian countries (8% ± 9%) than
in some Western countries (1% ± 3%) [10,18–22]. Koh et al. reported that, in classic HL patients,
EBER-positive patients had lower OS than EBER-negative patients [23]. A meta-analysis including 13
studies found that EBER positivity was correlated with adverse clinicopathologic features, worse clinical
course, and poor outcome [10]. Plasma EBV DNA, derived from the apoptosis of lymphoma cells, is
reported to be a surrogate biomarker of lymphoma load and may provide prognostic information [46,47].
EBV-associated viral proteins were found to play a crucial role in oncogenesis, including in the regulation
of proliferation, immune escape, metastasis, and epigenetic modifications [10,14–17]. Constitutive
expression of latent membrane protein 1 (LMP1) was found to lead to activation of NF-kB and JAK/STAT
signaling, which protects against apoptosis and activates autocrine/paracrine signals. This further
promotes tumor growth and immune evasion [17]. Additionally, previous studies proposed that
EBV may induce angiogenesis in the lymphoid tissue when LMP-1 activates angiogenetic factors [23].
Our study is the second study to focus on EBER expression in NP lymphoma. For cases (n = 32)
with EBER ISH staining results, 13 cases showed EBER positivity, including cases of NKTCL (n = 7,
100% of NKTCL cases with EBER ISH staining) (Figure 5), DLBCL (n = 5, 31.3% of DLBCL cases with
EBER ISH staining) (Figure 4), and PTLD (n = 1). The frequency of EBER positivity for DLBCL was
higher than in other studies. The five-year OS of EBER (+) and EBER (−) cases was 55.6% and 58.5%,
respectively. In the DLBCL subgroup, five-year OS for EBER (+) and EBER (−) cases was 50% and
85.7%, respectively. Although there was no significant difference, EBER-positive DLBCL patients had
poorer prognosis compared to EBER-negative DLBCL patients. The relationship of EBV infection with
prognosis in NP lymphoma needs further investigation in the future.
EBER ISH has been considered as the gold standard for evaluating EBER positivity for many
years. It allows a direct visualization of the neoplastic cells. However, it is a semi-quantitative analysis,
and subtle differences in technical quality cannot be eliminated [10]. More sensitive methods, such as
PCR for EBV viral load measurement, EBV-encoded miRNAs detection, and RNAscope assay, may
help to confirm whether there is EBV infection in EBER-negative samples [48,49]. However, the NP
tissue for PCR analysis should contain only tumor tissue, to avoid biased results.
Gene expression profıling can classify DLBCL into two clinically distinct subgroups, i.e., germinal
center B-cell (GCB) and non-GCB, which includes activated B-cell (ABC) [50,51]. The GCB subtype
is associated with better outcomes, while the ABC subtype is associated with worse outcomes [52].
Hans et al. divided DLBCL into GCB and non-GCB subgroups by using immunostaining for CD10,
bcl-6, and MUM1 and found an outcome similar to that predicted by cDNA microarray analysis [53].
Since our study is a retrospective study, we did not perform a cDNA microarray analysis to divide
our DLBCL cases into GCB or ABC. However, several cases were studied by IHC for CD10, bcl-6, and
MUM1 expression. Among these, there were one GCB and seven non-GCB lymphomas according to
Hans criteria (Supplementary Table S2). This may explain the relatively poor outcomes of our DLBCL
cases. Besides, a high proportion of stage IV patients (n = 5, 29.4%) were noted in our DLBCL patients.
None of our DLBCL patients relapsed with CNS disease.
NPC is also highly related to EBV, and more than 90% of NPC are EBER-positive. Therefore,
it is important to differentiate NP lymphomas from NPC, especially in areas with a high incidence
of NPC. NPC usually originates from the posterolateral nasopharynx at the fossa of Rosenmüller,
while NP lymphoma usually presents as diffuse swelling of NP under nasal endoscopic examination
(Figure 3). The surface of NP lymphomas may be inflamed, with a central necrotic area. According to
Liu’s research, NP lymphoma can be distinguished from NPC by MR imaging, for NPC tumor lesions
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are more likely to be asymmetrical and invade more deeply into tissues, while NP lymphomas are
usually symmetric and tend to spread laterally [36]. Otolaryngologists should be wary about making a
diagnosis of NP lymphoma, especially in areas endemic with NPC.
There are only few studies reporting the clinical characteristics and prognosis of NP lymphomas,
and most of them studied T-cell and B-cell lymphomas as a single group [2–4,6,8,9]. Very few
studies have specifically addressed the clinical disparities of NP-DLBCL and NP-NKTCL. Our study
demonstrated the differences between the two types and also investigated EBER expression in NP
lymphoma, especially in an area with high NPC occurrence. However, one limitation of this study is
that there was no certain way to determine whether stage IV disease originated from the nasopharynx
primarily. Larger-scale studies are needed in the future to better understand the development of this
rare disease.
5. Conclusions
NP lymphoma is a rare malignancy developing in the head and neck region and encompasses
a variety of histological subtypes. NP-DLBCL and NP-NKTCL are the two most common subtypes,
and there are several differences between them regarding clinical features and prognosis. In endemic
areas with a high frequency of NPC occurrence, NP lymphoma should always be considered in the
differential diagnosis when approaching a patient with a nasopharyngeal mass.
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